0	3	The	the	DT
4	14	peri-kappa	peri-kappa	NN
15	16	B	B	NNP
17	21	site	site	NN
22	30	mediates	mediate	VBZ
31	36	human	human	JJ
37	53	immunodeficiency	immunodeficiency	NN
54	59	virus	virus	NN
60	64	type	type	NN
65	66	2	2	CD
67	75	enhancer	enhancer	NN
76	86	activation	activation	NN
87	89	in	in	IN
90	99	monocytes	monocyte	NNS
100	103	but	but	CC
104	107	not	not	RB
108	110	in	in	IN
111	112	T	t	NN
113	118	cells	cell	NNS
118	119	.	.	.

121	126	Human	human	JJ
127	143	immunodeficiency	immunodeficiency	NN
144	149	virus	virus	NN
150	154	type	type	NN
155	156	2	2	CD
157	158	(	(	(
158	163	HIV-2	hiv-2	NN
163	164	)	)	)
164	165	,	,	,
166	170	like	like	IN
171	176	HIV-1	HIV-1	NNP
176	177	,	,	,
178	184	causes	cause	VBZ
185	189	AIDS	AIDS	NNP
190	193	and	and	CC
194	196	is	be	VBZ
197	207	associated	associate	VBN
208	212	with	with	IN
213	217	AIDS	AIDS	NNP
218	223	cases	case	NNS
224	233	primarily	primarily	RB
234	236	in	in	IN
237	241	West	West	NNP
242	248	Africa	Africa	NNP
248	249	.	.	.

250	255	HIV-1	HIV-1	NNP
256	259	and	and	CC
260	265	HIV-2	HIV-2	NNP
266	273	display	display	VBP
274	285	significant	significant	JJ
286	297	differences	difference	NNS
298	300	in	in	IN
301	308	nucleic	nucleic	JJ
309	313	acid	acid	NN
314	322	sequence	sequence	NN
323	326	and	and	CC
327	329	in	in	IN
330	333	the	the	DT
334	341	natural	natural	JJ
342	349	history	history	NN
350	352	of	of	IN
353	361	clinical	clinical	JJ
362	369	disease	disease	NN
369	370	.	.	.

371	381	Consistent	consistent	JJ
382	386	with	with	IN
387	392	these	these	DT
393	404	differences	difference	NNS
404	405	,	,	,
406	408	we	we	PRP
409	413	have	have	VBP
414	424	previously	previously	RB
425	437	demonstrated	demonstrate	VBN
438	442	that	that	IN
443	446	the	the	DT
447	464	enhancer/promoter	enhancer/promoter	NN
465	471	region	region	NN
472	474	of	of	IN
475	480	HIV-2	hiv-2	NN
481	490	functions	function	NNS
491	496	quite	quite	RB
497	508	differently	differently	RB
509	513	from	from	IN
514	518	that	that	DT
519	521	of	of	IN
522	527	HIV-1	HIV-1	NNP
527	528	.	.	.

529	536	Whereas	whereas	IN
537	547	activation	activation	NN
548	550	of	of	IN
551	554	the	the	DT
555	560	HIV-1	HIV-1	NNP
561	569	enhancer	enhancer	NN
570	579	following	follow	VBG
580	586	T-cell	t-cell	NN
587	598	stimulation	stimulation	NN
599	601	is	be	VBZ
602	610	mediated	mediate	VBN
611	618	largely	largely	RB
619	626	through	through	IN
627	634	binding	binding	NN
635	637	of	of	IN
638	641	the	the	DT
642	655	transcription	transcription	NN
656	662	factor	factor	NN
663	671	NF-kappa	NF-kappa	NNP
672	673	B	B	NNP
674	676	to	to	TO
677	680	two	two	CD
681	689	adjacent	adjacent	JJ
690	695	kappa	kappa	NN
696	697	B	b	NN
698	703	sites	site	NNS
704	706	in	in	IN
707	710	the	the	DT
711	716	HIV-1	HIV-1	NNP
717	721	long	long	JJ
722	730	terminal	terminal	JJ
731	737	repeat	repeat	NN
737	738	,	,	,
739	749	activation	activation	NN
750	752	of	of	IN
753	756	the	the	DT
757	762	HIV-2	hiv-2	NN
763	771	enhancer	enhancer	NN
772	774	in	in	IN
775	784	monocytes	monocyte	NNS
785	788	and	and	CC
789	790	T	t	NN
791	796	cells	cell	NNS
797	799	is	be	VBZ
800	809	dependent	dependent	JJ
810	812	on	on	IN
813	817	four	four	CD
818	828	cis-acting	cis-acting	JJ
829	837	elements	element	NNS
837	838	:	:	:
839	840	a	a	DT
841	847	single	single	JJ
848	853	kappa	kappa	NN
854	855	B	B	NNP
856	860	site	site	NN
860	861	,	,	,
862	865	two	two	CD
866	877	purine-rich	purine-rich	JJ
878	885	binding	bind	VBG
886	891	sites	site	NNS
891	892	,	,	,
893	897	PuB1	pub1	NN
898	901	and	and	CC
902	906	PuB2	pub2	NN
906	907	,	,	,
908	911	and	and	CC
912	913	a	a	DT
914	918	pets	pet	NNS
919	923	site	site	NN
923	924	.	.	.

925	927	We	we	PRP
928	932	have	have	VBP
933	936	now	now	RB
937	947	identified	identify	VBN
948	949	a	a	DT
950	955	novel	novel	JJ
956	966	cis-acting	cis-acting	JJ
967	974	element	element	NN
975	981	within	within	IN
982	985	the	the	DT
986	991	HIV-2	hiv-2	NN
992	1000	enhancer	enhancer	NN
1000	1001	,	,	,
1002	1013	immediately	immediately	RB
1014	1022	upstream	upstream	JJ
1023	1025	of	of	IN
1026	1029	the	the	DT
1030	1035	kappa	kappa	NN
1036	1037	B	B	NNP
1038	1042	site	site	NN
1042	1043	,	,	,
1044	1054	designated	designate	VBN
1055	1065	peri-kappa	peri-kappa	NN
1066	1068	B.	B.	NNP
1069	1073	This	this	DT
1074	1078	site	site	NN
1079	1081	is	be	VBZ
1082	1091	conserved	conserve	VBN
1092	1097	among	among	IN
1098	1106	isolates	isolate	NNS
1107	1109	of	of	IN
1110	1115	HIV-2	hiv-2	NN
1116	1119	and	and	CC
1120	1123	the	the	DT
1124	1131	closely	closely	RB
1132	1139	related	related	JJ
1140	1146	simian	simian	JJ
1147	1163	immunodeficiency	immunodeficiency	NN
1164	1169	virus	virus	NN
1169	1170	,	,	,
1171	1174	and	and	CC
1175	1187	transfection	transfection	NN
1188	1194	assays	assay	NNS
1195	1199	show	show	VBP
1200	1204	this	this	DT
1205	1209	site	site	NN
1210	1212	to	to	TO
1213	1220	mediate	mediate	VB
1221	1226	HIV-2	hiv-2	NN
1227	1235	enhancer	enhancer	NN
1236	1246	activation	activation	NN
1247	1256	following	follow	VBG
1257	1268	stimulation	stimulation	NN
1269	1271	of	of	IN
1272	1281	monocytic	monocytic	JJ
1282	1285	but	but	CC
1286	1289	not	not	RB
1290	1296	T-cell	t-cell	NN
1297	1302	lines	line	NNS
1302	1303	.	.	.

1304	1308	This	this	DT
1309	1311	is	be	VBZ
1312	1315	the	the	DT
1316	1321	first	first	JJ
1322	1333	description	description	NN
1334	1336	of	of	IN
1337	1339	an	an	DT
1340	1345	HIV-2	hiv-2	NN
1346	1354	enhancer	enhancer	NN
1355	1362	element	element	NN
1363	1368	which	which	WDT
1369	1377	displays	display	VBZ
1378	1382	such	such	JJ
1383	1391	monocyte	monocyte	NN
1392	1403	specificity	specificity	NN
1403	1404	,	,	,
1405	1408	and	and	CC
1409	1411	no	no	DT
1412	1422	comparable	comparable	JJ
1423	1431	enhancer	enhancer	NN
1432	1439	element	element	NN
1440	1443	has	have	VBZ
1444	1448	been	be	VBN
1449	1456	clearly	clearly	RB
1457	1464	defined	define	VBN
1465	1468	for	for	IN
1469	1474	HIV-1	HIV-1	NNP
1474	1475	.	.	.

1476	1481	While	while	IN
1482	1483	a	a	DT
1484	1491	nuclear	nuclear	JJ
1492	1501	factor(s)	factor(s)	NN
1502	1506	from	from	IN
1507	1511	both	both	CC
1512	1522	peripheral	peripheral	JJ
1523	1528	blood	blood	NN
1529	1538	monocytes	monocyte	NNS
1539	1542	and	and	CC
1543	1544	T	t	NN
1545	1550	cells	cell	NNS
1551	1556	binds	bind	VBZ
1557	1560	the	the	DT
1561	1571	peri-kappa	peri-kappa	NN
1572	1573	B	B	NNP
1574	1578	site	site	NN
1578	1579	,	,	,
1580	1595	electrophoretic	electrophoretic	JJ
1596	1604	mobility	mobility	NN
1605	1610	shift	shift	NN
1611	1617	assays	assay	NNS
1618	1625	suggest	suggest	VBP
1626	1630	that	that	IN
1631	1637	either	either	CC
1638	1639	a	a	DT
1640	1649	different	different	JJ
1650	1657	protein	protein	NN
1658	1663	binds	bind	VBZ
1664	1666	to	to	TO
1667	1671	this	this	DT
1672	1676	site	site	NN
1677	1679	in	in	IN
1680	1689	monocytes	monocyte	NNS
1690	1696	versus	versus	IN
1697	1698	T	t	NN
1699	1704	cells	cell	NNS
1705	1707	or	or	CC
1708	1712	that	that	IN
1713	1716	the	the	DT
1717	1724	protein	protein	NN
1725	1736	recognizing	recognize	VBG
1737	1741	this	this	DT
1742	1750	enhancer	enhancer	NN
1751	1758	element	element	NN
1759	1768	undergoes	undergo	VBZ
1769	1781	differential	differential	JJ
1782	1794	modification	modification	NN
1795	1797	in	in	IN
1798	1807	monocytes	monocyte	NNS
1808	1811	and	and	CC
1812	1813	T	t	NN
1814	1819	cells	cell	NNS
1819	1820	,	,	,
1821	1825	thus	thus	RB
1826	1836	supporting	support	VBG
1837	1840	the	the	DT
1841	1853	transfection	transfection	NN
1854	1858	data	datum	NNS
1858	1859	.	.	.

1860	1867	Further	further	RB
1867	1868	,	,	,
1869	1874	while	while	IN
1875	1883	specific	specific	JJ
1884	1896	constitutive	constitutive	JJ
1897	1904	binding	binding	NN
1905	1907	to	to	TO
1908	1911	the	the	DT
1912	1922	peri-kappa	peri-kappa	NN
1923	1924	B	B	NNP
1925	1929	site	site	NN
1930	1932	is	be	VBZ
1933	1937	seen	see	VBN
1938	1940	in	in	IN
1941	1950	monocytes	monocyte	NNS
1950	1951	,	,	,
1952	1963	stimulation	stimulation	NN
1964	1968	with	with	IN
1969	1976	phorbol	phorbol	NN
1977	1983	esters	ester	NNS
1984	1991	induces	induce	VBZ
1992	2002	additional	additional	JJ
2002	2003	,	,	,
2004	2012	specific	specific	JJ
2013	2020	binding	binding	NN
2020	2021	.	.	.

2022	2035	Understanding	understand	VBG
2036	2039	the	the	DT
2040	2057	monocyte-specific	monocyte-specific	JJ
2058	2066	function	function	NN
2067	2069	of	of	IN
2070	2073	the	the	DT
2074	2084	peri-kappa	peri-kappa	NN
2085	2086	B	B	NNP
2087	2093	factor	factor	NN
2094	2097	may	may	MD
2098	2108	ultimately	ultimately	RB
2109	2116	provide	provide	VB
2117	2124	insight	insight	NN
2125	2129	into	into	IN
2130	2133	the	the	DT
2134	2143	different	different	JJ
2144	2148	role	role	NN
2149	2158	monocytes	monocyte	NNS
2159	2162	and	and	CC
2163	2164	T	t	NN
2165	2170	cells	cell	NNS
2171	2175	play	play	VBP
2176	2178	in	in	IN
2179	2182	HIV	HIV	NNP
2183	2195	pathogenesis	pathogenesis	NN
2195	2196	.	.	.